Form 4: Director Hannah Valantine Receives PACB Stock Options

Director Hannah Valantine was granted 223,492 stock options in Pacific Biosciences of California, Inc. on June 3, 2026.

Summary

• Director Hannah Valantine received a grant of 223,492 stock options.
• The options have an exercise price of $1.58 per share.
• The grant date is June 3, 2026, with an expiration date of June 3, 2026.
• Vesting occurs monthly over a one-year period, contingent on continued service as a director.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock.
• Dependence on continued director service for full vesting of the options.

Future Outlook

The options vest monthly over one year, provided the director remains in service, aligning the director's tenure with company performance.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board alignment with long-term strategic goals.

Comparison to Industry Standards

• The one-year vesting schedule is consistent with standard director compensation packages for mid-cap biotech firms.
• The use of stock options as a primary incentive tool remains a common practice among life sciences companies to preserve cash.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if options are exercised.

Next Steps

• Vesting of options on a monthly basis starting July 3, 2026.

Key Dates

Keywords

PACB, Pacific Biosciences, Form 4, Insider Trading, Stock Options, Director Compensation